Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | GCLC | P48506 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL576209 | 0.80 | GRIK1 (0.60) | CA2MAPK1GRIK1GRIK2SLC1A3 | |
| SCHEMBL265349 | 0.75 | — | — | |
| SCHEMBL28212361 | 0.75 | CA2 (0.67) | CA2MAPK1GRIK1GRIK2SLC1A3 | |
| SCHEMBL27843743 | 0.75 | — | — | |
| SCHEMBL7144191 | 0.75 | — | — | |
| SCHEMBL2146877 | 0.73 | — | — | |
| SCHEMBL3104177 | 0.73 | — | — | |
| SCHEMBL6114 | 0.72 | — | — | |
| SCHEMBL3101364 | 0.72 | — | — | |
| Acetic Acid SCHEMBL18011985 | 0.71 | CA2 (0.61) | CA2MAPK1GRIK1GRIK2SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382205-B2 | Processes for the manufacture of a pharmaceutically active agent | H. LUNDBECK A/S (DK) | 2016-07-05 | — | — | US | claimed |
| US-20150080584-A1 | PROCESSES FOR THE MANUFACTURE OF A PHARMACEUTICALLY ACTIVE AGENT | H. LUNDBECK A/S (DK) | 2015-03-19 | — | — | US | claimed |
| US-20260144753-A1 | MULTIVALENT IONIZABLE LIPID DELIVERY SYSTEMS | FACTOR BIOSCIENCE INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026102133-A1 | MULTIVALENT IONIZABLE LIPID DELIVERY SYSTEMS | FACTOR BIOSCIENCE INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260124298-A1 | CLEC9A BINDING AGENTS | Orionis Biosciences BV (BE) | 2026-05-07 | — | — | US | disclosed |
| US-20260125473-A1 | CD8 BINDING AGENTS | ORIONIS BIOSCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115254-A1 | IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF | VIB VZW (BE) | 2026-04-30 | — | — | US | disclosed |
| US-20260109748-A1 | MODULATION OF DENDRITIC CELL LINEAGES | ORIONIS BIOSCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3580230-B1 | IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF | VIB VZW (BE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102512-A1 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR FANCONI ANEMIA | STRM BIO INCORPORATED (US) | 2026-04-16 | — | — | US | disclosed |
| US-12583941-B2 | Fibroblast activation protein binding agents and use thereof | ORIONIS BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-0736007-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0716854-A2 | Compositions for inhibiting neuropeptide y receptors | ELI LILLY AND COMPANY (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1996012489-A1 | BICYCLIC NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996012488-A1 | BICYCLIC BRADYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0709090-A2 | Compositions for treating resistant tumors | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995017095-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995017382-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583941-B2 | Fibroblast activation protein binding agents and use thereof | FAP, IGSF11, FIBP | CA2 3161/4885MAPK1 2512/4885GRIK1 4429/4885 |
| US-20260115254-A1 | IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF | SCTR, CSF1R, MSR1 | CA2 2693/4885MAPK1 1135/4885GRIK1 3721/4885 |
| US-20150080584-A1 | PROCESSES FOR THE MANUFACTURE OF A PHARMACEUTICALLY ACTIVE AGENT | CEL, DCPS, HPSE | CA2 2567/4885MAPK1 3121/4885GRIK1 4287/4885 |
| US-20260109748-A1 | MODULATION OF DENDRITIC CELL LINEAGES | FCGR3B, VSIG8, TNFRSF9 | CA2 3479/4885MAPK1 4232/4885GRIK1 3293/4885 |
| US-20260144753-A1 | MULTIVALENT IONIZABLE LIPID DELIVERY SYSTEMS | PLTP, SLC7A1, PCTP | CA2 1048/4885MAPK1 3963/4885GRIK1 3890/4885 |
| US-20260102512-A1 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR FANCONI ANEMIA | CD47, CD63, LAMP1 | CA2 4616/4885MAPK1 3262/4885GRIK1 3651/4885 |
| US-20260125473-A1 | CD8 BINDING AGENTS | CD74, IGSF11, CD81 | CA2 2311/4885MAPK1 3552/4885GRIK1 2123/4885 |
| US-20260124298-A1 | CLEC9A BINDING AGENTS | TNFRSF9, SIGLEC9, IGSF11 | CA2 3351/4885MAPK1 2116/4885GRIK1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.